Skip to main content

Table 1 Baseline characteristics of the study population according to low and high CV groups

From: Effects of metabolic parameters’ variability on cardiovascular outcomes in diabetic patients

 

SBP-CV

TC-CV

TG-CV

Glucose-CV

 

Low

(n = 11,155)

High

(n = 11,155)

p-value

Low

(n = 11,155)

High

(n = 11,155)

p-value

Low

(n = 11,155)

High

(n = 11,155)

p-value

Low

(n = 11,155)

High

(n = 11,155)

p-value

Age (years)

62.7 ± 10.6

66.9 ± 10.9

< 0.01

65.5 ± 10.8

64.1 ± 11.1

< 0.01

66.6 ± 10.8

63.0 ± 10.9

< 0.01

64.7 ± 10.6

64.9 ± 11.4

0.10

Male (n, %)

6,512 (58.4)

5,852 (52.5)

< 0.01

6,066 (54.4)

6,298 (56.5)

< 0.01

5,771 (51.7)

6,593 (59.1)

< 0.01

6,005 (53.8)

6,359 (57.0)

< 0.01

Alcohol (n, %)

2,580 (23.1)

2,801 (25.1)

< 0.01

2,478 (22.2)

2,903 (26.0)

< 0.01

2,471 (22.2)

2,910 (26.1)

< 0.01

2,495 (22.4)

2,886 (25.9)

< 0.01

Smoking (n, %)

2,104 (18.9)

2,430 (21.8)

< 0.01

2,020 (18.1)

2,514 (22.5)

< 0.01

2,067 (18.5)

2,467 (22.1)

< 0.01

1,922 (17.2)

2,612 (23.4)

< 0.01

Hypertension (n, %)

8,219 (73.7)

9,500 (85.2)

< 0.01

8,901 (79.8)

8,818 (79.1)

0.17

9,030 (90.0)

8,689 (77.9)

< 0.01

8,638 (77.4)

9,081 (81.4)

< 0.01

Dyslipidemia (n, %)

10,025 (89.9)

10,160 (91.1)

< 0.01

10,069 (90.3)

10,116 (90.7)

0.28

10,059 (90.2)

10,126 (90.8)

0.13

10,069 (90.3)

10,116 (90.7)

0.28

Prior MI (n, %)

406 (3.6)

487 (4.4)

< 0.01

448 (4.0)

445 (4.0)

0.92

460 (4.1)

433 (3.9)

0.36

403 (3.6)

490 (4.4)

< 0.01

Prior stroke (n, %)

1,271 (11.4)

2,006 (18.0)

< 0.01

1,695 (15.2)

1,582 (14.2)

0.03

1,775 (15.9)

1,502 (13.5)

< 0.01

1,544 (13.8)

1,733 (15.5)

< 0.01

SCORE2 (n, %)

  

< 0.01

  

0.19

  

< 0.01

  

< 0.01

- low-moderate risk

5,128 (46.0)

3,356 (30.1)

 

4,267 (38.3)

4,217 (37.8)

 

3,840 (34.4)

4,644 (41.6)

 

4,604 (41.3)

3,880 (34.8)

 

- high risk

3,841 (34.4)

3,944 (35.4)

 

3,928 (35.2)

3,857 (34.6)

 

3,881 (34.8)

3,904 (35.0)

 

3,921 (35.2)

3,864 (34.6)

 

- very high risk

2,186 (19.6)

3,855 (34.6)

 

2,960 (26.5)

3,081 (27.6)

 

3,434 (30.8)

2,607 (23.4)

 

2,630 (23.6)

3,411 (30.6)

 

SBP-CV (%)

6.5 ± 1.5

11.6 ± 2.7

< 0.01

8.6 ± 3.2

9.5 ± 3.5

< 0.01

9.0 ± 3.3

9.1 ± 3.4

< 0.01

8.4 ± 3.1

9.7 ± 3.5

< 0.01

TC-CV (%)

12.3 ± 7.1

14.0 ± 8.2

< 0.01

7.6 ± 2.3

18.7 ± 7.3

< 0.01

11.5 ± 6.6

14.7 ± 8.5

< 0.01

11.9 ± 7.0

14.4 ± 8.2

< 0.01

TG-CV (%)

28.7 ± 15.4

29.3 ± 15.7

< 0.01

25.7 ± 13.0

32.3 ± 17.1

< 0.01

18.1 ± 5.4

39.9 ± 14.8

< 0.01

27.4 ± 14.6

30.6 ± 16.3

< 0.01

Glucose-CV (%)

16.5 ± 11.5

21.9 ± 14.8

< 0.01

16.8 ± 12.0

21.6 ± 14.6

< 0.01

17.9 ± 12.8

20.5 ± 14.2

< 0.01

9.3 ± 3.5

29.1 ± 12.7

< 0.01

Baseline SBP (mmHg)

128.6 ± 12.4

130.6 ± 18.1

< 0.01

128.9 ± 14.9

130.4 ± 16.2

< 0.01

129.3 ± 15.4

129.9 ± 15.7

< 0.01

128.6 ± 14.7

130.6 ± 16.4

< 0.01

Baseline TC (mg/dL)

157.2 ± 36.6

156.6 ± 45.2

0.260

149.9 ± 30.4

164.0 ± 48.6

< 0.01

152.8 ± 36.1

161.0 ± 45.2

< 0.01

157.4 ± 35.7

156.4 ± 45.9

0.075

Baseline TG (mg/dL)

147.8 ± 98.6

150.1 ± 103.1

0.088

134.2 ± 79.1

163.6 ± 116.9

< 0.01

130.6 ± 68.2

167.2 ± 122.6

< 0.01

141.0 ± 86.3

156.8 ± 113.1

< 0.01

Basline glucose (mg/dL)

141.1 ± 51.1

146.8 ± 65.0

< 0.01

138.0 ± 46.9

149.9 ± 67.7

< 0.01

140.3 ± 53.3

147.5 ± 63.1

< 0.01

129.5 ± 33.3

158.4 ± 73.0

< 0.01

Mean SBP (mmHg)

127.9 ± 9.5

128.6 ± 11.1

< 0.01

127.9 ± 10.2

128.5 ± 10.5

< 0.01

128.2 ± 10.5

128.3 ± 10.2

0.25

127.5 ± 10.0

128.9 ± 10.7

< 0.01

Mean TC (mg/dL)

149.8 ± 27.3

147.6 ± 28.6

< 0.01

146.3 ± 26.3

151.1 ± 29.5

< 0.01

146.2 ± 27.0

151.2 ± 28.7

< 0.01

150.8 ± 27.3

146.6 ± 28.6

< 0.01

Mean TG (mg/dL)

139.9 ± 70.8

142.7 ± 75.1

< 0.01

129.4 ± 59.1

153.3 ± 83.0

< 0.01

125.0 ± 54.8

157.6 ± 84.4

< 0.01

135.0 ± 65.0

147.7 ± 79.7

< 0.01

Mean glucose (mg/dL)

134.8 ± 27.1

137.8 ± 33.1

< 0.01

133.4 ± 27.5

139.2 ± 32.5

< 0.01

134.0 ± 28.0

138.7 ± 32.1

< 0.01

126.2 ± 21.8

146.4 ± 33.9

< 0.01

RAS blocker (%)

6,492 (58.2)

8,032 (72.0)

< 0.01

7,349 (65.9)

7,175 (64.3)

0.01

7,485 (67.1)

7,039 (63.1)

< 0.01

6,925 (62.1)

7,599 (68.1)

< 0.01

DHP-CCB (%)

4,639 (41.6)

5,962 (53.5)

< 0.01

5,301 (47.5)

5,300 (47.5)

0.99

5,496 (49.3)

5,105 (45.8)

< 0.01

5,049 (45.3)

5,552 (49.8)

< 0.01

Beta-blocker (%)

2,860 (25.6)

4,243 (38.0)

< 0.01

3,496 (31.3)

3,607 (32.3)

0.11

3,670 (32.9)

3,433 (30.8)

< 0.01

3,338 (29.9)

3,765 (33.8)

< 0.01

Diuretics (%)

3,857 (34.6)

5,212 (46.7)

< 0.01

4,504 (40.4)

4,565 (40.9)

0.41

4,712 (42.2)

4,357 (39.1)

< 0.01

4,216 (37.8)

4,853 (43.5)

< 0.01

Statin (%)

8,842 (79.3)

8,955 (80.3)

0.06

9,110 (81.7)

8,687 (77.9)

< 0.01

9,066 (81.3)

8,731 (78.3)

< 0.01

8,960 (80.3)

8,837 (79.2)

0.04

Insulin (%)

3,492 (31.3)

4,761 (42.7)

< 0.01

3,953 (35.4)

4,300 (38.6)

< 0.01

4,221 (37.8)

4,032 (36.2)

< 0.01

3,065 (27.5)

5,188 (46.5)

< 0.01

  1. Categorical variables in n (%) and continuous variables in mean ± standard deviation
  2. CCB, calcium channel blocker; CV, coefficient of variability; DHP, dihydropyridine; MI, myocardial infarction; RAS, renin-angiotensin system; SBP, systolic blood pressure; TC, total cholesterol; TG, triglyceride